News Channels

17 Jan 2020 First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
17 Jan 2020 BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
17 Jan 2020 Rybelsus label updated with additional information from the PIONEER 6 CV outcomes trial
16 Jan 2020 PlantForm advances HIV antibody research in collaboration with scientists funded by U.S. National Institutes of Health
16 Jan 2020 Fibrocor and Galapagos sign expanded collaboration in fibrosis
15 Jan 2020 RECORDATI: Isturisa® (osilodrostat) approved
15 Jan 2020 Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products
15 Jan 2020 Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
15 Jan 2020 Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy
15 Jan 2020 Janssen Seeks Expanded Use of SPRAVATO (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
15 Jan 2020 Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
15 Jan 2020 Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
15 Jan 2020 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
15 Jan 2020 UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
15 Jan 2020 Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
15 Jan 2020 Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase
15 Jan 2020 Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
15 Jan 2020 Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
15 Jan 2020 NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
15 Jan 2020 New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up